<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> (LS) is an inherited <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-predisposing disorder caused by germline mutations in the mismatch repair (MMR) genes </plain></SENT>
<SENT sid="1" pm="."><plain>The high variability in individual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk observed among LS patients suggests the existence of modifying factors </plain></SENT>
<SENT sid="2" pm="."><plain>Identifying genetic modifiers of risk could help implement personalized surveillance programs based on predicted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks </plain></SENT>
<SENT sid="3" pm="."><plain>Here we evaluate the role of the telomerase (hTERT) rs2075786 SNP as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-risk modifier in LS, studying 255 and 675 MMR gene mutation carriers from Spain and the Netherlands, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The study of the Spanish sample revealed that the minor allele (A) confers increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk at an early age </plain></SENT>
<SENT sid="5" pm="."><plain>The analysis of the Dutch sample confirmed the association of the A allele, especially in homozygosity, with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in mutation carriers under the age of 45 (relative risk(LSca&lt;45_AA)=2.90; 95% confidence interval=1.02-8.26) </plain></SENT>
<SENT sid="6" pm="."><plain>Rs2075786 is associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) risk neither in the general population nor in non-Lynch <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> families </plain></SENT>
<SENT sid="7" pm="."><plain>In silico studies predicted that the SNP causes the disruption of a transcription binding site for a <z:chebi fb="0" ids="26537">retinoid</z:chebi> receptor, <z:chebi fb="0" ids="26537">retinoid</z:chebi> X receptor alpha, probably causing early telomerase activation and therefore accelerated <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Notably, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-affected LS patients with the AA genotype have shorter telomeres than those with GG </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, MMR gene mutation carriers with hTERT rs2075786 are at high risk to develop a LS-related <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> at an early age </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-preventive measures and stricter <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> surveillance at early ages might help prevent or early detect <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in these mutation carriers.European Journal of Human Genetics advance online publication, 5 September 2012; doi:10.1038/ejhg.2012.204 </plain></SENT>
</text></document>